CURRENT NEWS

• 14.06.2019
  New Data Presented at 24th EHA Congress From Oncopeptides' Phase 1/2 ANCHOR Trial Evaluating Melflufen in Relapsed/Refractory Multiple Myeloma (RRMM)
• 14.06.2019
  OneFifteen Opens the First of Its State-Of-The-Art Facilities for the Treatment of Opioid Use Disorder in Dayton, Ohio
• 14.06.2019
  Bluebird Bio Presents Long-Term Efficacy and Safety Data From Clinical Studies of LentiGlobin Gene Therapy for Transfusion-Dependent ?-Thalassemia (TDT) at 24th European Hematology Association (EHA) Congress
• 14.06.2019
  Bluebird Bio Presents New Data for LentiGlobin Gene Therapy for Sickle Cell Disease (SCD) at 24th European Hematology Association (EHA) Congress
• 14.06.2019
  LifeArc Invests £1.5 Million in Ducentis BioTherapeutics
• 14.06.2019
  Chi-Med Announces That Surufatinib Phase III SANET-Ep Study Has Met Its Primary Endpoint at Interim Analysis in Advanced Non-Pancreatic Neuroendocrine Tumors in China and Will Stop Early
• 14.06.2019
  G1 Therapeutics to Present Patient-Reported Outcomes (PRO) Data on Trilaciclib at Multinational Association of Supportive Care in Cancer (MASCC) and International Society of Oral Oncology (ISCOO) 2019 Annual Meeting
• 14.06.2019
  Kura Oncology Announces Positive Phase 2 Trial of Tipifarnib in Peripheral T-Cell Lymphoma
• 14.06.2019
  Aptose Presents New Preclinical Data for CG-806 at the 24th Congress of the European Hematology Association
• 14.06.2019
  Tauriga Sciences, Inc. Incorporates Private Limited Company in Belfast, Northern Ireland
• 14.06.2019
  Sorrento Therapeutics to Present at the JMP Securities Life Sciences Conference in New York (NY)
• 14.06.2019
  CytoDyn Raises Over $12 Million in New Capital From Private and Public Warrant Offers in the Last Five Weeks With Minimum Dilution
• 14.06.2019
  Amarillo Completes Non-Brokered Private Placement for Gross Proceeds of Approximately $5.3 Million
• 14.06.2019
  Ampio Regulatory and Clinical Update
• 14.06.2019
  Regeneron CD20xCD3 Bispecific REGN1979 Shows Positive Results in Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma, Including in CAR-T Failures
• 14.06.2019
  Lilly Presents Positive Results for Taltz (Ixekizumab) vs. Humira (Adalimumab) in a Head-To-Head (SPIRIT-H2H) Superiority Study in Patients With Active Psoriatic Arthritis at the European Congress of Rheumatology
• 14.06.2019
  BerGenBio Presents Preliminary Phase II Clinical Data at EHA 24: Bemcentinib in Combination With Low Dose Chemotherapy Yields Durable Responses in AML Patients Unfit for Intensive Chemotherapy
• 14.06.2019
  Janssen Reports Top-Line Phase 3 Results for TREMFYA (Guselkumab) in Adults With Active Psoriatic Arthritis
• 14.06.2019
  UCB's Key Pipeline Molecule Bimekizumab Demonstrated Improved Outcomes for Ankylosing Spondylitis Patients
• 14.06.2019
  Positive Phase 3 Extension Data for ULTOMIRIS (Ravulizumab) in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Presented at European Hematology Association (EHA) Congress

Records per page:

Page

Total: 38538 records.